Advertisement


Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

2022 ASCO Annual Meeting

Advertisement

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Michael Overman: Takayuki, great to have you here. Really exciting that you're here presenting the PARADIGM data. Congratulations on such a large, meaningful frontline study. First of all, can you tell us the design and then the primary endpoint and what that outcome was, to start with? Takayuki Yoshino: Thank you very much. The PARADIGM study is the first prospective study to test the superiority of panitumumab over the bevacizumab in combination with the standard chemo, modified FOLFOX6 treatment, in patients with RAS wild-type metastatic colorectal cancer in the first-line setting. Primary endpoint in this study is the overall survival in the left-sided population, defined as descending colon, sigmoid colon, rectosigmoid, and/or rectum. We also adopt in a hierarchical way, if the OS in the left-sided is of statistical significance, we move over to test the OS in the overall population, defined as both left-sided and right-sided primary tumor location, regardless of the primary tumor location. And so this is our current study design. Of course, we also calculate the number, 800 patients, needed to conduct this study in overall population. Michael Overman: So, positive study for the primary endpoint, correct? Takayuki Yoshino: Yes. Yeah, yes. Michael Overman: For overall survival. Maybe one of the questions we can dive in a little bit is the PFS curves overlay, and yet you have that overall survival separation, which is similar to what we've seen before with the FIRE-3 data. What is your explanation or hypothesis for that kind of finding that we've seen before? Takayuki Yoshino: Yeah. Yeah. Thank you very much. So I believe that, consistent with the previous report, that PFS is consistent between two arms, as expected. Another indicator of difference, favoring panitumumab is the response rate, depth of response, and also the curative resection rate. So I believe that such other factors as depth of response, curative resection, response rate, also be associated with a prolonged overall survival. In addition, this study, I mentioned about the subsequent level is a very similar second line over. So I believe that these three factors mostly important. In addition, our trial PFS definition of the event of the PFS is that if the patient who receive the curative intent surgery transferring before progression without surgery. So this transferring the method also will diminish the OS, PFS benefit. I believe that. Michael Overman: Okay. It's good to hear. I agree. There's a lot of questions on why, and I think I kind of agree with all those and that leads to the overall survival separated later on, 28-month delay. And I think, in part, you would say the same reasons, maybe that depth of a response that curative resection intent would be why we see that separation later? Takayuki Yoshino: Yes. PFS is very comparable similar to that today, the 28 months from randomization. Curve is completely overlapped. However, from the 28 from randomization, separation bigger. And then this separation is gradually bigger and bigger: three-year time point, four-year time, five-year time point. This trial with a median follow-up of 61 months, so five year. I believe that this late separation associated with the maximum tumor shrinkage as well as the R0 resection, both. Michael Overman: Yeah, no, makes sense. For the take home for the audience and the practitioners, now what is your statement on left-sided RAS/RAF wild-type patients? What is the standard that you would say then, for now? Takayuki Yoshino: My takeaway message that current to the US condition that circumstance, many doctors still use the bevacizumab in the first-line over anti-EGFR antibody. Two important factors are the skin toxicity issue, as well, the timing of the last testing. US is still not require initiating treatment. So I want to say that considering the balance of the calcium toxicity, still panitumumab should establish a new standard of care RAS wild-type on the left-sided population. So US physician also, reconsider about the testing timing of the last before initiation of the first-line therapy. And then of course during the managing toxicity, skin toxicity especially, and then you should consider the anti-EGFR antibodies in the first-line setting over bevacizumab, is my takeaway message. Michael Overman: Yeah, no, I agree with you. I think the data we're seeing and accumulated and really your data confirming that we really need to think differently and move more to that anti-EGFR space on the left RAS/RAF wild-type side. So I completely agree with you and again, thank you for that fantastic data. Takayuki Yoshino: Yes. Thank you very much. Yeah. I'm very excited. Thank you very much.

Related Videos

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).

Supportive Care

Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions

Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses clinical trial findings on the best ways to integrate community-based interventions into cancer care delivery for low-income and minority populations. Such interventions may improve quality of life and patient activation (often defined as patients having the knowledge, skills, and confidence to manage their health), as well as reduce hospitalizations and the total costs of care (Abstract 6500).

Breast Cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).

Gynecologic Cancers

Bradley J. Monk, MD, on Ovarian Cancer: New Data on Rucaparib Monotherapy vs Placebo as Maintenance Treatment

Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based chemotherapy, improved progression-free survival in patients with ovarian cancer, irrespective of homologous recombination deficiency status (Abstract LBA5500).

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).

Advertisement

Advertisement



Advertisement